Dr. Shiva Gopal Vasishta is a well-known psychiatrist and neurologist based in Voorhees, New Jersey. He earned a medical degree from the Government Medical College in 1979 and has a vast experience of over 40 years in the medical field. Dr. Shiva Vasishta signed up for residency at the Tufts Medical Center and the Boston City Hospital. He presently practices medicine at Eastern Neurodiagnostic Associates, and he is also associated with Kennedy Health System Cherry Hill Campus. Dr. Shiva accepts a range of insurance plans in his treatment programs such as Horizon Blue Cross, Blue Shield, Aetna, and the Medicare.
Dr. Shiva Gopal Vasishta is licensed by the Board of Neurology as a qualified and experienced practitioner. He works as a member of the Eastern Neurodiagnostic Association PC Group. As one of the few certified neurologist, Dr. Shiva Vasishta treats epilepsy, seizures, headache, dementia, stroke, sleep disorders, MS, and neuromuscular ailments.
The new NIH study shows that stem-cell transplants may be the next great hope in the fight against MS. The medication is known as high-dose immunosuppressive therapy and autologous hematopoietic cell transplant. The participants of this study received a one-time treatment of HDIT/HCT, and 69% of the participants experienced no relapse, progression of symptoms, or new brain lesions.
The ground-breaking study, commonly known as HALT-MS, was launched in December 2014 with the financial help from Immune Tolerance Network and was sponsored by National Institute of Allergy and Infectious Diseases. It was concluded on February 2017 and the research findings documented in a medical journal called Neurology, which is published by the American Academy of Neurology. The Director of NIAD’s branch of transplantation, allergy, and immunology, Dr. Daniel Rotrosen, revealed that the new multiple sclerosis treatments would be a ground-breaking innovation for the medical world. He also said that patients suffering from relapsing MS and those who do not recover from MS after using conventional MS drugs would benefit from the HDIT/HCT.